The total authorization was 550,000,000 K shares.
FIT Biotech’s Board of Directors has resolved to issue 100,000,000 new K shares without payment to the Company itself based on the authorization granted by the extraordinary general meeting on December 14, 2017 (Extraordinary general meeting Point 9§).
The total authorization was 550,000,000 K shares. The Board of Directors has decided earlier on December 27, 2017 to issue 80,000,000 new K shares. There are authorizations for 370,000,000 K shares left after this issuance.
The purpose is partly to use the shares to implement the new Alpha Blue Ocean funding programme, disclosed on December 23, 2017 and partly to implement the remaining part of the Bracknor funding programme.
FIT BIOTECH OY
Board of Directors
For further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080
E-mail: erkki.pekkarinen@fitbiotech.com
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media
